Dr. Makhlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Fl 10
Philadelphia, PA 19104Phone+1 410-955-7911Fax+1 215-662-7352
Education & Training
- Johns Hopkins UniversityFellowship, Medical Oncology, 2015 - 2018
- Johns Hopkins UniversityResidency, Internal Medicine, 2015 - 2018
- Commonwealth Medical CollegeClass of 2015, MD
Certifications & Licensure
- PA State Medical License 2018 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Member - Alpha Omega Alpha Alpha Omega Alpha, 2015
- Clinical Scholar Award The Commonwealth Medical College, 2015
- Excellence in Internal Medicine Award The Commonwealth Medical College, 2015
Publications & Presentations
PubMed
- 1 citationsTargeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor-Positive Breast Cancer: ASCO Guideline Clinical Insights.Igor Makhlin, Lesley Fallowfield, N Lynn Henry, Harold J Burstein, Mark R Somerfield
JCO Oncology Practice. 2024-08-27 - 6 citationsAdverse Cardiovascular Events Associated With Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer.Michael G Fradley, Nam H K Nguyen, David Madnick, Yiqing Chen, Angela DeMichele
Journal of the American Heart Association. 2023-06-20 - 29 citationsThe mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancersIgor Makhlin, Jiaru Zhang, Christopher J. Long, Karthik Devarajan, Yan Zhou
BJU International. 2011-07-01
Research History
- Cell Signaling Cancer ResearchInvestigated role of mTOR blockade in urothelial carcinoma. Also investigated SH2 domain profiling as means to predict chemotherapy response for kidney cancer.2009 - 2011
Professional Memberships
- Member
- Member
- Member
Other Languages
- Russian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: